ArticlePregnancy (Hoboken, N.J.)2025
Risk of hypertensive disorders in pregnancies with non-immune hydrops fetalis and single fetal effusions.
Article in Pregnancy (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Introduction: Hydrops fetalis carries high risks of morbidity and mortality for the fetus, as well as obstetric risks such as hypertensive disorders, or mirror syndrome, for the pregnant person. We aimed to characterize the prevalence and types of hypertensive disorders diagnosed in pregnancies with non-immune hydrops fetalis and single effusions, as well as to investigate fetal risk factors for the development of hypertension. Methods: This was a secondary analysis of a prospectively enrolled cohort. We included pregnancies with non-immune hydrops fetalis that demonstrated ≥2 fetal effusions (ascites, pleural effusion, pericardial effusion, and/or skin edema), as well as pregnancies with only one of these effusions. We excluded pregnancies that did not continue beyond 20 weeks gestation as most hypertensive disorders of pregnancy develop after this. Primary outcomes were the prevalence and types of hypertensive disorders diagnosed during pregnancy or within 6 weeks postpartum. Secondary outcomes were the prevalence of hypertensive disorders by number of fetal effusions and presence of an underlying fetal genetic disease. Results: Among 116 pregnancies with fetal effusions, 22 (19%) developed hypertensive disorders of pregnancy, with 22% (19/85) and 10% (3/31) of pregnancies with non-immune hydrops fetalis and single effusions affected, respectively ( Conclusions: In this contemporary cohort that continued beyond 20 weeks gestation, 22% with non-immune hydrops fetalis and 10% with single effusions developed a range of hypertensive disorders of pregnancy, with most arising in the antepartum period. These data allow clinicians to provide more evidence-based counseling, anticipate obstetric risks, and consider close surveillance strategies for the development of hypertensive disorders in pregnancies with fetal effusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.